MedTrace Logo

Colonoscopy Screening: Setting Epic Follow-up Times

NCT05631873 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2024-03-12

No results posted yet for this study

Summary

Screening for colorectal cancer can reduce its incidence and mortality but is a complex, error-prone process. The value of screening with colonoscopy is in removing pre-cancerous polyps that increase one's risk for future cancer. Abnormal results are common, and failure to receive recommended follow-up undermines the benefits of screening, violates the trust that patients place in their providers, and increases medicolegal risk. This proposal seeks to ensure that the foundation of safety systems, the recommendations for the follow-up interval reflect current guideline recommendations and are accurately updated. Specifically, the investigators will implement and evaluate in a randomized trial a new colonoscopy result letter as part of usual care that automatically updates the recommended follow-up interval in the patient's health record compared to the current result letter format.

Conditions

  • Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart
  • Colorectal Cancer

Interventions

OTHER

Assistance with implementing Epic Smartlist

A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records

Sponsors & Collaborators

  • Harvard Risk Management Foundation

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-18
Primary Completion
2023-09-30
Completion
2024-03-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05631873 on ClinicalTrials.gov